Breathe BioMedical Inc. is a medical technology company. It is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breath analytics involves the collection, processing, and analysis of breath samples to identify biomarker patterns associated with specific diseases. It is developing a proprietary end-to-end breath analytics platform, the intended use of which is to enable breath testing for the detection of disease. Its platform technology combines three advanced technologies to sample, digitize and analyze breath with the potential to detect multiple diseases. Its spectrometer technology uses Cavity Ring-Down Spectroscopy (CRDS) to measure the volatile organic compounds (VOCs) in breath samples which are collected using its breath sampler device (SohnoXB). Spectrometer is designed to be very fast, permitting sample analysis down to parts-per-trillion levels.
Símbolo de cotizaciónBRTH
Nombre de la empresaBreathe BioMedical Inc
Fecha de salida a bolsa- -
Director ejecutivoDawes (William)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscal- -
Dirección191 Halifax Street
CiudadMONCTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalE1C 9R7
Teléfono19024148148
Sitio Webhttps://breathebiomedical.com/
Símbolo de cotizaciónBRTH
Fecha de salida a bolsa- -
Director ejecutivoDawes (William)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos